Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 8351-8360 Newer>

Chemistry World June 28, 2012 Patrick Walter	FDA green lights new obesity drug Lorcaserin, which has been developed by US-based Arena Pharmaceuticals, in conjunction with Japan's Eisai, is the first obesity prescription medicine approved for 13 years.
Chemistry World June 26, 2012 Sarah Houlton	Roche rapped for side-effect reporting failure Roche has been rapped by the European Medicines Agency for failing to report a large number of potential drug side-effects. The UK's Medicines and Healthcare products Regulatory Agency identified deficiencies in the company's medicine safety reporting system.
Chemistry World June 26, 2012 Patrick Walter	Roche cuts 1000 jobs with US R&D site closure The shuttering of its only East Coast R&D site is part of a streamlining drive which will see research activities from the Nutley site moved to Germany and Switzerland.
Chemistry World June 20, 2012	Nasonex patent ruling goes against Merck & Co The US court ruled that, although the Merck patent in question was valid, it should not stop Canadian generics company Apotex marketing its mometasone furoate product.
Fast Company Jul/Aug 2012 Farhad Manjoo	Big Changes Are Ahead For The Healthcare Industry, Courtesy Of Big Data The importance of Big Data transcends its big hype. There are so many blue-sky proclamations for what's become known as Big Data that you need a data scientist to track them all.
Pharmaceutical Executive June 1, 2012	Gamification Grows Up Early efforts to harness the engagement factor in game technology focused on delivering a fun experience, with a tacked-on educational component. Today's games bring behavior change to the forefront, incorporating social dynamics, mobility, and increasingly sophisticated mechanics.
Pharmaceutical Executive June 1, 2012	2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead.
Pharmaceutical Executive June 1, 2012 Mark Chataway	Can Social Media Give Big Pharma Back its Reputation? The industry's ability to master the external environment depends on making the 140-character shorthand of the Twitter generation its own.
Pharmaceutical Executive June 1, 2012	Raising the Stakes in CNS As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory.
Pharmaceutical Executive June 1, 2012	A Brand Positioning Nightmare New drug indications can be a brand manager's worst nightmare or a dream come true. The difference lies in the perspective and in the branding strategy.
<Older 8351-8360 Newer> Return to current articles.